Myeloproliferative Neoplasm
Conditions
Brief summary
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
0 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria. * Signature of the consent form for participation in the FIMBANK project. * Agreement to participate in the VYP study. * Patient of legal age at the time of inclusion in VYP. * Patient affiliated to a social security scheme
Exclusion criteria
* Refusal to participate by patients of full age * Patient under legal protection (guardianship, curatorship, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the epidemiological characteristics of the study population | at enrollment | Description of MPN subtypes according to age |
| Describe the mutational landscape of these MPNs | at enrollment | Rate of mutations JAK2/CALR/MPL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1 | At 10 years | Incidence of thrombosis |
| Describe the classical MPN outcomes-2 | At 10 years | Incidence of myelofibrosis |
| Describe the classical MPN outcomes-3 | At 10 years | Incidence of MDS/AML |
Countries
France
Contacts
Primary ContactJean-Christophe IANOTTO
Outcome results
None listed